Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Bone Metabolism Markers in Thalassemia Major-Induced Osteoporosis: Results from a Cross-Sectional Observational Study

Author(s): Athanasios N. Tsartsalis*, George I. Lambrou, Dimitrios N. Tsartsalis, Ioannis Papassotiriou, Eugenia Vlachou, Evaggelos Terpos, George P. Chrousos, Christina Kanaka-Gantenbein and Antonis Kattamis

Volume 19, Issue 5, 2019

Page: [335 - 341] Pages: 7

DOI: 10.2174/1566524019666190314114447

Price: $65

Abstract

Background: Thalassemia major (TM) patients eventually face many new health conditions, including endocrinopathies and low bone mineral density, usually observed in the aging general population.

Objective: The aim of the current study was to evaluate the biomarkers of bone remodeling in TM patients and to compare them with both osteoporotic and healthy population, in order to investigate the new therapeutic paths.

Methods: Sixty-four patients with TM (32 men and 32 women) participated in the study. The patients were evaluated with dual-energy X-ray absorptiometry (DXA) of the lumbar spine and femoral neck and with markers of bone remodeling including receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG), C-terminal telopeptide (CTX), and sclerostin. Results were compared with those from 12 postmenopausal women with osteoporosis and 12 women with normal bone mineral density.

Results: The statistical analysis of the biochemical markers of bone metabolism revealed overall significant differences between the three groups only for RANKL and OPG/RANKL (p=0.049 and p=0.009). RANKL was higher and OPG/RANKL was lower in TM patients compared to osteoporosis group.

Conclusion: Patients with TM do not have a higher probability of suffering from osteoporosis from the general population. However, some markers of osteoclast activity differ between patients with TM and osteoporosis, indicating the possible differences in terms of anti-osteoporotic treatment. The lack of significant differences among the three groups in regards to the levels of CTX and sclerostin may indicate the potential efficacy of the current osteoporotic treatment also for TM patients.

Keywords: Osteoporosis, Thalassemia Major, sclerostin, RANKL, OPG, endocrinopathies, bone metabolism.

« Previous Next »
[1]
Weatherall DJ. In:The Molecular Basis of Blood Diseases. Stamatoyannopoulos, G,Nienhuis, AW,Majerus, PW,Varmus, H, Eds. Philadelphia, PA: WB Saunders. 1994; p. 815.
[2]
Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000; 111: 902-7.
[3]
Sharma R, Seth A, Chandra J, et al. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy. Paediatr Int Child Health 2016; 36: 22-7.
[4]
Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, et al. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int 1999; 64: 481-4.
[5]
Voskaridou E, Stoupa E, Antoniadou L, et al. Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica 2006; 91: 813-6.
[6]
Spatz JM, Wein MN, Gooi JH, et al. The Wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J Biol Chem 2015; 290: 16744-58.
[7]
McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-20.
[8]
van Dinther M, Zhang J, Weidauer SE, et al. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One 2013; 8: e62295.
[9]
Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375: 1532-43.
[10]
Voskaridou E, Anagnostopoulos A, Konstantopoulos K, et al. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 2006; 91: 1193-202.
[11]
Morabito N, Gaudio A, Lasco A, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004; 19: 722-7.
[12]
Meena MC, Hemal A, Satija M, Arora SK, Bano S. Comparison of bone mineral density in thalassemia major patients with healthy controls. Adv Hematol 2015; 2015: 648349.
[13]
Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001; 112: 36-41.
[14]
Gratwick GM, Bullough PG, Bohne WH, Markenson AL, Peterson CM. Thalassemic osteoarthropathy. Ann Intern Med 1978; 88: 494-501.
[15]
De Sanctis V, Pinamonti A, Di Palma A, et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996; 155: 368-72.
[16]
Lasco A, Morabito N, Gaudio A, et al. Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 2002; 25: 338-44.
[17]
Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280: 19883-7.
[18]
Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011; 6: e25900.
[19]
Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, et al. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv 2018; 2: 2837-47.
[20]
Gaudio A, Morabito N, Catalano A, et al. Pathogenesis of thalassemia major-associated osteoporosis: Review of the literature and our experience. J Clin Res Pediatr Endocrinol 2018.
[21]
Geusens P. New insights into treatment of osteoporosis in postmenopausal women. RMD Open 2015; 1: e000051.
[22]
MacNabb C, Patton D, Hayes JS. Sclerostin antibody therapy for the treatment of osteoporosis: Clinical prospects and challenges. J Osteoporos 2016; 2016: 6217286.
[23]
Voskaridou E, Christoulas D, Plata E, et al. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 2012; 44: 909-13.

Rights & Permissions Print Cite
Article Metrics
20
3
© 2024 Bentham Science Publishers | Privacy Policy